At Lilly, we understand that people living with AD don’t have time to waste, which is why, for more than three decades, we’ve remained committed to taking on AD from every angle. Our vision is that in 10 years’ time, timely detection, accurate diagnosis, appropriate treatment and ultimately prevention will become a reality.

Yet, we understand that for this to become a reality, collaboration, partnership, and new approaches are required. This is why we are proud to join forces with the EFPIA AD platform to ‘ensure a brighter today and tomorrow for people with Alzheimer’s Disease’ and hope to encourage the wider decision maker community to get involved so that, together, we can improve the lives of millions of people around the world.

Click Here to read more.